Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14 results about "Endocarditis" patented technology

Infection of the endocardium, usually involving heart valves.

Lactobacilli for treating cardiac dysfunction

The use of a bacterium of the species Lactobacillus salivarius in the manufacture of a food product, dietary supplement or medicament for treating cardiac dysfunction, particularly myocardial infarction, congestive heart failure, dilated cardiomyopathy or inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis) is disclosed.
Owner:INT N&H DENMARK APS

Preparation of nano-drug with NO catalytic performance and application of nano-drug in treatment of infectious endocarditis

The invention discloses preparation of a nano-drug with NO catalytic performance and application of the nano-drug in treatment of infectious endocarditis. The preparation method comprises the following steps: respectively dissolving molybdate and hydrophosphate in water, then stirring and mixing the two solutions, and carrying out self-assembly to form oxidized molybdenum-based Keggin type heteropolyacid, namely the nano-drug (OX) with NO catalytic performance. The nano-drug prepared by the invention has GSNO catalytic characteristics and multiple antibacterial characteristics, also has antithrombotic and vascular regulation functions, can efficiently catalyze endogenous GSNO to generate NO, and realizes efficient treatment of infectious endocarditis through the synergistic effect of double functions of oxidation antibacterial-NO regulation.
Owner:JINAN UNIVERSITY

Preparation of nano-drug with NO catalytic performance and application thereof in treatment of infective endocarditis

The application discloses a kind of nano-medicines with NO catalytic performance and its application in infective endocarditis treatment.The application dissolves molybdate and hydrogen phosphate in water respectively, then the two solutions are stirred and mixed to form Keggin type heteropoly acid of oxidized molybdenum base by self-assembly, i.e., the nano-medicines with NO catalytic performance (OX).The nano-medicines prepared by the application have GSNO catalytic properties and multiple antibacterial properties, and also have antithrombotic and vascular regulation functions, can efficiently catalyze endogenous GSNO to generate NO, through the synergistic effect of "oxidation antibacterial-NO regulation" dual functions, to realize efficient treatment of infective endocarditis.
Owner:JINAN UNIVERSITY

Peripheral leakage prevention support device and heart valve

PendingCN121101809ABalloon catheterHeart valvesEndocarditisThrombus
The invention discloses a peripheral leakage prevention stent device convenient to load and a heart valve, the peripheral leakage prevention stent device comprises a stent and is further provided with a flexible skirt edge, and the skirt edge has a spreading state in which the skirt edge axially extends and surrounds the periphery of the stent before being released; and in the stacking state, the annular peripheral leakage plugging part is driven by deformation when the stent is released and is folded and stacked in the axial direction of the released stent to form the annular peripheral leakage plugging part. By means of the peripheral leakage prevention technology, the interventional stent is more matched with the inner wall of a blood vessel, the stent is not prone to displacement and is more stable, the range of applicable people is widened, additional risks of operations are reduced, and complications such as peripheral leakage and thrombus are prevented and treated. Better hemodynamic performance is provided, the host endothelial cell climbing and covering function is enhanced, the occurrence probability of endocarditis is reduced, and the normal blood supply function of heart and blood vessels is recovered.
Owner:VENUS MEDTECH (HANGZHOU) INC

Application of alpha-hederin in preparation of medicine for preventing or treating staphylococcus aureus infectious diseases

PendingCN121846112Aenhance immune responsefight infectionAntibacterial agentsOrganic active ingredientsInfected cellDisease
The invention discloses application of alpha-hederin in preparation of a medicine for preventing or treating staphylococcus aureus infectious diseases, and belongs to the technical field of medicines. The staphylococcus aureus infectious disease is one of skin or soft tissue infection, pneumonia, osteoarthritis, mastitis, enteritis, endocarditis, urinary tract infection and enteritis. The medicine does not have an in-vitro direct sterilization function on sensitive and methicillin-resistant staphylococcus aureus, but can remarkably promote infected cells to remove thalli under a cell infection condition, so that the medicine plays a role in resisting sensitive and methicillin-resistant staphylococcus aureus infection by improving the anti-infection immune level of the cells.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI

A cloxacillin sodium composition and preparation method thereof

Cloxacillin Sodium is an organic compound with the molecular formula C 19 H 18 Cl2N3NaO6S. It is a white powder or crystalline powder; slightly smelly and bitter; hygroscopic. Cloxacillin sodium is prepared into an injection for administration, which is mainly used to treat penicillinase-producing Staphylococcus aureus infections, including sepsis, endocarditis, pneumonia, and skin and soft tissue infections. Because it has multiple easily hydrolyzed groups, such as β-lactam rings and amide bonds, it has poor stability and is easily hydrolyzed. In order to improve the stability of cloxacillin sodium, the present invention uses Bicine (N,N-bis(hydroxyethyl)glycine) as a buffer salt and CMC / AA / AM as a hygroscopic agent (carboxymethyl cellulose (CMC) connected to acrylic acid (AA) connected to acrylamide (AM)), and adopts a sterile packaging process to obtain a highly stable cloxacillin sodium preparation.
Owner:CHENGDU BRILLIANT PHARMA CO LTD

Enterococcus faecalis vaccine and uses thereof

The present disclosure provides immunogenic compositions comprising at least one recombinant polypeptide antigen derived from an Enterococcus bacterium (e.g., E. faecalis, E. faecium, E. durans). The disclosure further provides methods, and uses of the immunogenic compositions, for protecting or treating a subject from infection by an Enterococcus bacterium. Such infections may cause, or worsen, conditions such as root canal failure, endocarditis, bacteremia, urinary tract infections, prostatitis, intraabdominal infection, cellulitis, dysbiotic gastrointestinal tract, prosthetic joint infection, or wound infections.
Owner:VAXCYTE INC +1

Serum metabolism marker combination for diagnosing and classifying infectious endocarditis and screening method thereof

PendingCN121725908AMolecular entity identificationPreparing sample for investigationLaser desorption ionization mass spectrometryScreening method
The invention discloses a serum metabolism marker combination for diagnosing and classifying infectious endocarditis and a screening method thereof, and relates to the technical field of biological science. According to the method, a serum metabolism fingerprint spectrum is obtained through a matrix-assisted laser desorption / ionization mass spectrometry (MALDI MS) technology, and feature screening and model construction are carried out in combination with multiple machine learning models (including ridge regression, random forest, LASSO regression and the like). Through machine learning, five-fold cross validation is adopted to optimize model performance, and independent queue verification is utilized to evaluate generalization ability and overfitting risk. According to the technical scheme, rapid diagnosis and classification of IE can be achieved within 10 minutes, the pretreatment process is simple (an existing IE diagnosis method is complex in process and consumes 2-5 days), the requirements of clinical IE rapid screening and large-scale sample analysis can be met, and the method is suitable for industrial production. The detection flux is obviously improved; the cost is reduced.
Owner:SHANGHAI JIAOTONG UNIV

Infectious endocarditis pathogen detection kit based on digital PCR platform, application and detection method

The invention discloses an infectious endocarditis pathogen detection kit based on a digital PCR (Polymerase Chain Reaction) platform, application and a detection method. The kit comprises a primer probe mixed solution, a PCR premixed solution, a bacterial solution containing an internal standard sequence fragment, and a positive quality control product and a negative quality control product of inactivated engineering bacteria containing a target gene fragment. The kit is used for detecting 15 infectious endocarditis pathogenic microorganisms and methicillin drug-resistant genes mecA and mecC in one tube. In practical application tests, even if the concentration of pathogens is as low as less than 10 copies per milliliter, the pathogens can be accurately identified, and extremely high sensitivity is shown. And synchronous detection of multiple pathogens and drug resistance thereof can be rapidly completed within 2 hours without waiting for a blood culture result.
Owner:NANJING STONE GENE TECHNOLOGY CO LTD

Pharmaceutical composition for preventing or treating penicillin-based compound-resistant bacteria-mediated diseases comprising oxazolidinone derivative

A pharmaceutical composition according to one aspect comprises an oxazolidinone derivative or a pharmaceutically acceptable salt thereof, and thus can exhibit excellent prophylactic or therapeutic effects on diseases mediated by bacteria having resistance to penicillin-based compounds, and in particular, when used in combination with one or more antibiotics, can exhibit excellent effects such as an increase in overall healing rate, elimination of mediating bacteria, inhibition of an increase in severity, inhibition of occurrence of adverse events, an increase in safety, an increase in tolerability, and the like. Accordingly, the composition can be used as a therapeutic agent for penicillin-based compound-resistant bacteria-mediated diseases such as bacteremia, sepsis, endocarditis, and the like.
Owner:LIGACHEM BIOSCIENCES INC

Use of amiloride in the preparation of a drug for preventing and treating infective endocarditis or inhibiting its pathogenic bacteria

ActiveCN116211863BAntibacterial agentsOrganic active ingredientsEndarteritisAmiloride
The present invention provides an application of amiloride in the preparation of a drug for preventing and treating infective endocarditis or inhibiting its pathogenic bacteria, belonging to the field of pharmaceutical technology. The results show that after treatment with amiloride, the vacuoles of macrophages disappear significantly, the release of LDH decreases significantly, and macrophage death is significantly reduced. At the same time, the results also show that injecting amiloride can significantly inhibit the pathogenic bacteria of endocarditis, thereby effectively treating infective endocarditis. Therefore, the present invention discloses for the first time that amiloride can prevent and treat infective endocarditis, and amiloride itself is a drug for clinical application with high safety. Therefore, the present invention provides a theoretical basis for new substances for treating infective endocarditis and has broad application prospects.
Owner:SHANDONG UNIV

Skirt wrinkled stent device and heart valve

PendingCN121221323ABalloon catheterHeart valvesEndocarditisThrombus
The invention discloses a stent device with a folded skirt and a heart valve, the stent device comprises a stent and is further provided with a flexible skirt, and the skirt has a spreading state in which the skirt axially extends and surrounds the periphery of the stent before release; and in the stacking state, the annular peripheral leakage plugging part is driven by deformation when the stent is released and is folded and stacked in the axial direction of the released stent to form the annular peripheral leakage plugging part. By means of the peripheral leakage prevention technology, the interventional stent is more matched with the inner wall of a blood vessel, the stent is not prone to displacement and is more stable, the range of applicable people is widened, additional risks of operations are reduced, and complications such as peripheral leakage and thrombus are prevented and treated. Better hemodynamic performance is provided, the host endothelial cell climbing and covering function is enhanced, the occurrence probability of endocarditis is reduced, and the normal blood supply function of heart and blood vessels is recovered.
Owner:VENUS MEDTECH (HANGZHOU) INC

Products and methods for inducing immune response against bacteria

The present invention relates to peptides, fusion proteins and compositions for inducing an immune response against bacteria. The invention also relates to the treatment or prevention of infections by sepsis-inducing bacteria, and to the treatment and prevention of pathological conditions caused by such bacteria. Such pathological conditions include sepsis, pneumonia, meningitis, endocarditis, enterocolitis, urinary tract infection, soft tissue infection, gastrointestinal tract infection, bloodstream infection, encephalitis, premature delivery and dead delivery.
Owner:IMMUNOTHERAPY CO

Methods of treatment of alcohol associated hepatitis

PCT designated stageWO2026024792A1Organic active ingredientsAntibacterial agentsDiseaseHepatitis alcohol
Alcohol-associated liver disease, particularly alcohol-associated hepatitis, constitutes a significant global health burden with high mortality rates. Imbalances in the gut microbiota are important for the progression of alcohol-associated liver disease, a condition classified as non-infectious. Disclosed herein are methods of treating or ameliorating a symptom of alcohol-associated hepatitis and methods of reducing or preventing mortality associated with alcohol-associated hepatitis. Also disclosed herein are methods of treating or ameliorating a symptom of sepsis, urinary tract infection, pneumonia, intra-abdominal infections, and / or endocarditis. Further disclosed are methods of determining responsiveness of a subject to treatment with the small molecule inhibitor C7, methods of identifying a subject for a clinical trial for treatment for alcohol-associated hepatitis and methods of screening for candidate compounds for treating alcohol-associated hepatitis.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +2